Irritable Bowel Syndrome in China: A Comprehensive Review

0
0
0

Irritable Bowel Syndrome in China: A Comprehensive Review of Epidemiology, Diagnosis, and Management

Irritable bowel syndrome (IBS) is a globally prevalent functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. In China, IBS presents unique epidemiological patterns, diagnostic challenges, and management approaches influenced by sociocultural and environmental factors. This review synthesizes critical findings from Chinese studies to highlight distinctions from Western research and provide insights into the disease’s burden, clinical presentation, and therapeutic strategies in the Chinese population.

Epidemiology of IBS in China

The prevalence of IBS in China varies significantly depending on diagnostic criteria, study populations, and geographic regions. Nationwide surveys using Rome III criteria estimate an adult prevalence of 5%–10%, while stricter Rome IV criteria yield lower rates (2.3%–3.8%). Regional studies highlight disparities:

  • Hangzhou (Zhejiang Province): A household survey of 2,115 adults reported a prevalence of 5.9% using Rome III criteria, with diarrhea-predominant IBS (IBS-D) as the most common subtype.
  • Shanghai: A large-scale study of 7,648 adults identified a prevalence of 13.1% using Rome III criteria, with IBS-D and mixed subtypes (IBS-M) predominating.
  • Student populations: Medical students aged 18–23 exhibited alarmingly high rates (33.3%), suggesting stress and lifestyle factors as contributors.

Risk Factors

Key risk factors identified in Chinese cohorts include:

  • Psychological disorders: Anxiety, depression, and insomnia strongly correlate with IBS. A meta-analysis of 76,763 subjects confirmed psychological distress as a significant predictor.
  • Gastrointestinal infections: Post-infectious IBS (PI-IBS) is prevalent, with prior bacterial or viral gastroenteritis increasing susceptibility.
  • Dietary triggers: Cold, spicy, or greasy foods; alcohol; and dairy products exacerbate symptoms in 55%–66% of patients.
  • Demographics: Females are more prone to constipation-predominant IBS (IBS-C), while males show higher IBS-D rates.

Diagnostic Challenges and Criteria

Rome Criteria Adaptation

The transition from Rome III to Rome IV criteria has reduced diagnostic sensitivity in China. Rome IV requires abdominal pain as a mandatory symptom, excluding bloating and discomfort—common complaints in Chinese patients. Studies comparing criteria found:

  • Rome III diagnosed IBS in 12.4% of patients vs. 6.1% with Rome IV.
  • Over 30% of patients present with bloating or discomfort without pain, leading to underdiagnosis under Rome IV.

Symptom Overlap and Misdiagnosis

IBS frequently overlaps with upper functional gastrointestinal disorders (FGIDs):

  • Functional dyspepsia (FD): 77% of IBS patients report postprandial fullness, belching, or regurgitation, often leading to unnecessary proton pump inhibitor (PPI) use.
  • Misdiagnosis risks: Alarm symptoms (e.g., weight loss, rectal bleeding) are rare in Chinese IBS patients under 50, but endoscopic evaluation remains crucial to exclude organic diseases like inflammatory bowel disease (IBD).

Biomarkers and Diagnostic Tools

Emerging biomarkers aim to improve diagnostic accuracy:

  • Fecal calprotectin: Elevated in IBD but not IBS, aiding differentiation.
  • Intestinal fatty acid-binding protein (I-FABP): Higher in PI-IBS-D patients, suggesting intestinal barrier dysfunction.
  • Small intestinal bacterial overgrowth (SIBO): Breath tests (lactulose/glucose hydrogen) combined with scintigraphic transit measurements improve SIBO detection. Duodenal mucosal microbiota analysis shows promise in predicting SIBO in IBS-D.

Management Strategies

Dietary Interventions

Chinese dietary habits influence IBS management:

  • Trigger foods: Cold, spicy, and greasy foods are widely reported triggers. Personalized exclusion diets alleviate symptoms in 55% of patients.
  • Fat intake: High-fat diets correlate with SIBO-positive IBS-D, exacerbating abdominal pain and methane production.

Pharmacological Treatments

Antispasmodics

  • Pinaverium bromide: A multicenter RCT demonstrated significant improvements in abdominal pain, stool frequency, and discomfort in IBS-D patients.
  • Drotaverine hydrochloride: Reduces pain and normalizes stool patterns across IBS subtypes.

Antibiotics

  • Rifaximin: Effective in SIBO-positive IBS-D, improving symptoms and quality of life. Trials show superior outcomes when breath hydrogen rises ≥5 ppm before cecal contrast arrival.

Secretagogues

  • Linaclotide: Approved by China’s National Medical Products Administration (NMPA), this guanylate cyclase-C agonist alleviates constipation, bloating, and pain in IBS-C. A phase III trial reported sustained efficacy over 12 weeks.

Gut Microbiota Modulation

  • Probiotics: Clostridium butyricum and multi-strain formulations (e.g., Bifidobacterium, Lactobacillus) reduce diarrhea and pain.
  • Fecal microbiota transplantation (FMT): In refractory IBS, FMT improves symptom severity, anxiety, and depression scores, with effects lasting ≥3 months.

Traditional Chinese Medicine (TCM)

  • Tongxieyaofang (TXYF): This herbal formula outperforms placebos in relieving diarrhea, pain, and discomfort. Meta-analyses confirm its superiority over conventional antispasmodics.
  • Acupuncture: Electroacupuncture matches loperamide in reducing stool frequency and Bristol scores in IBS-D. A multicenter RCT showed sustained benefits for IBS-C and IBS-D over 12 weeks.

Conclusion

IBS in China exhibits distinct epidemiological and clinical profiles shaped by cultural, dietary, and diagnostic nuances. The lower sensitivity of Rome IV criteria risks underdiagnosis, necessitating adaptation to local symptom patterns. Management integrates dietary modifications, targeted pharmacotherapy, and TCM, reflecting China’s unique healthcare landscape. Future research must prioritize biomarker validation, criteria refinement, and personalized therapies to address this growing public health burden.

doi.org/10.1097/CM9.0000000000001550

Was this helpful?

0 / 0